Selected article for: "logistic regression analysis and lymphocyte count"
Author: Gude, Francisco; Riveiro, Vanessa; Rodríguez-Núñez, Nuria; Ricoy, Jorge; Lado-Baleato, Óscar; Lourido, Tamara; Rábade, Carlos; Lama, Adriana; Casal, Ana; Abelleira-París, Romina; Ferreiro, Lucía; Suárez-Antelo, Juan; Toubes, María E.; Pou, Cristina; Taboada-Muñiz, Manuel; Calle-Velles, Felipe; Mayán-Conesa, Plácido; del Molino, María L. Pérez; Galbán-Rodríguez, Cristóbal; Álvarez-Escudero, Julián; Beceiro-Abad, Carmen; Molinos-Castro, Sonia; Agra-Vázquez, Néstor; Pazo-Núñez, María; Páez-Guillán, Emilio; Varela-García, Pablo; Martínez-Rey, Carmen; Pernas-Pardavila, Hadrián; Domínguez-Santalla, María J.; Vidal-Vázquez, Martín; Marques-Afonso, Ana T.; González-Quintela, Arturo; González-Juanatey, José R.; Pose, Antonio; Valdés, Luis
Title: Development and validation of a clinical score to estimate progression to severe or critical state in COVID-19 pneumonia hospitalized patients
  • Cord-id: g3cwb4wd
  • Document date: 2020_11_13
    • ID: g3cwb4wd
    Snippet: The prognosis of a patient with COVID-19 pneumonia is uncertain. Our objective was to establish a predictive model of disease progression to facilitate early decision-making. A retrospective study was performed of patients admitted with COVID-19 pneumonia, classified as severe (admission to the intensive care unit, mechanic invasive ventilation, or death) or non-severe. A predictive model based on clinical, laboratory, and radiological parameters was built. The probability of progression to seve
    Document: The prognosis of a patient with COVID-19 pneumonia is uncertain. Our objective was to establish a predictive model of disease progression to facilitate early decision-making. A retrospective study was performed of patients admitted with COVID-19 pneumonia, classified as severe (admission to the intensive care unit, mechanic invasive ventilation, or death) or non-severe. A predictive model based on clinical, laboratory, and radiological parameters was built. The probability of progression to severe disease was estimated by logistic regression analysis. Calibration and discrimination (receiver operating characteristics curves and AUC) were assessed to determine model performance. During the study period 1152 patients presented with SARS-CoV-2 infection, of whom 229 (19.9%) were admitted for pneumonia. During hospitalization, 51 (22.3%) progressed to severe disease, of whom 26 required ICU care (11.4); 17 (7.4%) underwent invasive mechanical ventilation, and 32 (14%) died of any cause. Five predictors determined within 24 h of admission were identified: Diabetes, Age, Lymphocyte count, SaO(2), and pH (DALSH score). The prediction model showed a good clinical performance, including discrimination (AUC 0.87 CI 0.81, 0.92) and calibration (Brier score = 0.11). In total, 0%, 12%, and 50% of patients with severity risk scores ≤ 5%, 6–25%, and > 25% exhibited disease progression, respectively. A risk score based on five factors predicts disease progression and facilitates early decision-making according to prognosis.

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8
    • accurate diagnosis and adaptive immune response: 1
    • accurate diagnosis and admission hospitalization: 1
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and additive model: 1, 2
    • acute ards respiratory distress syndrome and administer tocilizumab: 1
    • acute ards respiratory distress syndrome and admission hospitalization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute ards respiratory distress syndrome and admission record: 1, 2
    • acute ards respiratory distress syndrome and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and liver kidney disease: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute respiratory distress and additive model: 1, 2
    • acute respiratory distress and administer tocilizumab: 1
    • acute respiratory distress and admission hospitalization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute respiratory distress and admission record: 1, 2
    • acute respiratory distress and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
    • adaptive immune response and admission hospitalization: 1, 2
    • adaptive immune response and liver kidney: 1, 2
    • admission hospitalization and liver kidney: 1, 2, 3, 4